	US 11,730,790 B2
	Mutant NGAL proteins and uses thereof
Jonathan Barasch, New York, NY (US); and Andong Qiu, Bronx, NY (US)
Assigned to The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed by The Trustees of Columbia University in the City of New York, New York, NY (US)
Filed on Mar. 16, 2020, as Appl. No. 16/819,891.
Application 15/376,327 is a division of application No. 13/684,060, filed on Nov. 21, 2012, granted, now 9,534,027, issued on Jan. 3, 2017.
Application 16/819,891 is a continuation of application No. 15/376,327, filed on Dec. 12, 2016, granted, now 10,588,937.
Application 13/684,060 is a continuation in part of application No. PCT/US2011/037774, filed on May 24, 2011.
Claims priority of provisional application 61/354,973, filed on Jun. 15, 2010.
Claims priority of provisional application 61/347,587, filed on May 24, 2010.
Prior Publication US 2021/0038686 A1, Feb. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 38/17 (2006.01); C07K 14/47 (2006.01); A61K 31/357 (2006.01)

CPC A61K 38/1709 (2013.01) [C07K 14/47 (2013.01); A61K 31/357 (2013.01)]

11 Claims

1. A polypeptide that comprises an amino acid sequence that is at least 99% identical to a sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 or SEQ ID NO:5.